Dept. Biochemical Sciences A. Rossi Fanelli, Sapienza University of Rome, Rome, Italy.
Institute of Molecular Biology and Pathology, Italian National Research Council IBPM-CNR, Rome, Italy.
Mol Aspects Med. 2023 Oct;93:101205. doi: 10.1016/j.mam.2023.101205. Epub 2023 Jul 27.
Anthracyclines have been important and effective treatments against a number of cancers since their discovery. However, their use in therapy has been complicated by severe side effects and toxicity that occur during or after treatment, including cardiotoxicity. The mode of action of anthracyclines is complex, with several mechanisms proposed. It is possible that their high toxicity is due to the large set of processes involved in anthracycline action. The development of resistance is a major barrier to successful treatment when using anthracyclines. This resistance is based on a series of mechanisms that have been studied and addressed in recent years. This work provides an overview of the anthracyclines used in cancer therapy. It discusses their mechanisms of activity, toxicity, and chemoresistance, as well as the approaches used to improve their activity, decrease their toxicity, and overcome resistance.
自发现以来,蒽环类药物一直是治疗多种癌症的重要且有效的药物。然而,由于在治疗过程中或治疗后会出现严重的副作用和毒性,包括心脏毒性,因此其在治疗中的应用变得复杂。蒽环类药物的作用模式很复杂,提出了几种机制。它们的高毒性可能是由于涉及蒽环类药物作用的一系列过程。当使用蒽环类药物时,耐药性的发展是成功治疗的主要障碍。这种耐药性基于近年来研究和解决的一系列机制。这项工作提供了癌症治疗中使用的蒽环类药物的概述。它讨论了它们的作用机制、毒性和化疗耐药性,以及用于提高其活性、降低其毒性和克服耐药性的方法。